ACKNOWLEDGMENTS
Anne-Marie
The authors acknowledge the editorial assistance of Richard S. Perry, in the preparation of this manuscript, which was supported by Spero Therapeutics, Cambridge, MA. The authors also would like to acknowledge the contributions of Karen Moran, Patricia Warfel, Anne-Marie Phelan, Emily Stone, Susannah Walpole, Augustina Gyimah, and Andrew Baranauskas from Spero Therapeutics, Gary Maier, from Maier Metrics, Danielle Armas, principal investigator from Celerion, Inc., and subjects who participated in the study, and Charles River Laboratories, Inc.All authors performed data analysis and interpretation, as well as manuscript review and approval.G.P. and L.G. are consultants for Spero Therapeutics, Inc. All other authors were paid employees of Spero Therapeutics, Cambridge, MA at the time of this study.This study was supported by Spero Therapeutics, Cambridge, MA.